Golden
Oxford BioMedica

Oxford BioMedica

Gene and cell therapy group focused on developing life changing treatments for serious diseases.

Oxford BioMedica is a publicly traded, gene and cell therapy group based in Oxford, Oxforshire, UK. The company and its subsidiaries (the "Group") have build a lentiviral delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products, both in-house and with partners. Its portfolio ranges across the areas of oncology, opthalmology, and CNS disorders.



Within its pipeline, Oxford BioMedica has several proprietary products, partnered products, and IP enabled and royalty bearing products. Its proprietary products, which would either be spun-out or licensed out, include:

  • OXB-202 - gene based treatment for corneal graft rejection. Phase 1/2 clinical studies are in preparation.
  • OXB-302 - gene based immunotherapy targeting a range of cancers. Pre-clinical studies are complete.
  • OXB-201 - gene therapy for wet AMD. Phase 1 clinical trials have been completed.
  • OXB-204 - in pre-clinical studies
  • OXB-208 - in pre-clinical studies
  • OXB-103 - in pre-clinical studies



The company's partnered products include:

  • AXO-LENTI-PD - gene therapy threatment for Parkinson's disease. Phase 1/2 clinical studies in preparation. Partnered with Axovant.
  • SAR 422459 - gene therapy for Stargardt disease. Phase 2 clinical studies ongoing. Licensed to Sanofi.
  • SAR 421869 - gene therapy for Usher syndrome type 1B. Phase 1/2a clinical trials ongoing. Licensed to Sanofi.



Additionally, Oxford BioMedica has multiple partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.





Timeline

People

Name
Role
Related Golden topics

Andrew Heath

Deputy Chairman & Senior Independent Director



Dr. Lorenzo Tallarigo

Chairman



Heather Preston

Independent Non-Executive Director



Helen Stephenson-Ellis

Chief People Officer



James Miskin

Chief Technical Officer



Jason Slingsby

Chief Business Officer



John Dawson

CEO



Kyriacos Mitrophanous

Chief Scientific Officer



Lisa Giles

Chief Projects and Performance Officer



Martin Diggle

Non-Executive Director



Nick Page

COO



Stuart Henderson

Independent Non-Executive Director



Stuart Paynter

CFO



Further reading

Title
Author
Link
Type
Date

Oxford BioMedica announces further capacity expansion with new facility

Oxford BioMedica plc

Web



Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

biopharma-reporter.com

Web



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References